News about Clinical Trials

AusperBio Doses First Patient in HBV Candidate AHB-171 Study

AusperBio has dosed the first patient in the AHB-171 clinical study, advancing its HBV pipeline and proprietary Au-HALO liver-targeting delivery technology siRNA platform.

Clinical Trials | 03/08/2026 | By News Bureau

Novo Nordisk Provides Phase 3 ZEUS Trial Update

Novo Nordisk shared an update on the phase 3 ZEUS trial evaluating patients with ASCVD, CKD and inflammation enrolled in a placebo-controlled study.

Clinical Trials | 03/08/2026 | By News Bureau

GlycoNex Doses First Patient in Phase 1 Trial of GNX1021

GlycoNex dosed the first patient in its phase 1 trial of GNX1021, advancing its glycan-directed Antibody Drug Conjugate (ADC) while exploring global licensing and co-development deals.

Clinical Trials | 03/08/2026 | By News Bureau

Moleculin Reports Encouraging Interim Phase 2/3 Data for Annamycin in Relapsed or Refractory AML

Moleculin Biotech has reported encouraging preliminary blinded data from its pivotal Phase 2/3 MIRACLE trial, with Annamycin plus cytarabine achieving a 37 percent composite complete remission rate in relapsed or refractory acute myeloid leukaemia.

Clinical Trials | 03/08/2026 | By News Bureau

Pfizer Reports Positive Phase 3 Results for LITFULO in Vitiligo

Pfizer's phase 3 studies showed LITFULO significantly improved facial and total repigmentation in patients with nonsegmental vitiligo versus placebo.

Clinical Trials | 31/07/2026 | By News Bureau

Hansoh Pharma Reports Positive Phase 3 Results for Ris-Rez in China

Hansoh Pharma reported positive phase 3 results for Ris-Rez in China, while GSK advances development across lung cancer, prostate cancer and other solid tumors.

Clinical Trials | 31/07/2026 | By News Bureau

Akeso Doses First Patient in Phase 1b/2 Trial of HER3 ADC for Advanced Lung Cancer

Akeso has dosed the first patient in its Phase 1b/2 AK138D1-201 trial, assessing the HER3-targeted antibody-drug conjugate AK138D1 as monotherapy and in combination with ivonescimab for patients with advanced non-small cell lung cancer.

Clinical Trials | 30/07/2026 | By News Bureau

ProMIS Neurosciences Reports Positive Interim Phase 1b Results for Alzheimer's Therapy PMN310

ProMIS Neurosciences has reported positive six-month interim data from its Phase 1b PRECISE-AD trial, with PMN310 demonstrating a favourable safety profile, no ARIA-E cases and encouraging biomarker trends in patients with Alzheimer's disease.

Clinical Trials | 30/07/2026 | By News Bureau |  127

Estrella Doses First Patient in EB103 Dose-Expansion Trial for Relapsed/Refractory B-Cell NHL

Estrella Immunopharma advances its STARLIGHT-1 Phase I/II trial with the first patient dosed in the EB103 dose-expansion cohort, building on promising early efficacy in relapsed/refractory B-cell non-Hodgkin’s lymphoma.

Clinical Trials | 28/07/2026 | By News Bureau

Ultomiris Misses Phase 3 Endpoint in Post-Transplant TMA Trial

AstraZeneca shares a phase 3 update on Ultomiris for Haematopoietic Stem Cell Transplant (HSCT)-TMA, showing a trend toward clinical benefit in adults and adolescents as regulatory discussions continue.

Clinical Trials | 28/07/2026 | By News Bureau